VentureBlick

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales. Over the years, HealthCap companies have developed more than 25 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.

Through its activities, Technology Ventures facilitates promising inventions to improve the quality of life for patients around the world. The mission of Technology Ventures is to promote the commercial development of Cedars‑Sinai research into products and services that advance healthcare and improve patient wellbeing. Technology Ventures actively seeks industry partners to develop these technologies and works to establish mutually beneficial long‑term relationships.

Pureland Global Venture is a direct investment fund and part of the Pureland Group which targets impact investment deals in the medical technology sector. We are Singapore-based with a focus in APAC, India and the US. The fund deals with early-stage companies who have potential to inject value into the patient care system, save lives and reduce gaps in the supply and demand chains. Since we were established, we have invested in multiple medical sectors in both medical devices and ML-based solutions. MISSION - WHAT WE WANT TO ACHIEVE Established with the goal of giving people access to healthcare and also providing them with clinical choices, our mission is to bring medical solutions and savings to 100 million people around the world. We strongly believe in people who don’t just care about profit and who want to make the world a better place by solving real issues and pushing forward the latest evolution in medical technology. We envision bringing together impactful start-ups, commercial partners, insightful advisors and clinical providers in order to build a sustainable foundation for affordable, accessible and high-quality healthcare. WHY HEALTHCARE? Worldwide healthcare spending is expected to continue to rise at an alarming rate with a slight difference in some countries. Of all the leading factors, life expectancy appears to still be on the rise. By 2050, 1/6 people in the world will be over the age of 65 (16%), an increase from 1/11 in 2019 (9%). The number of people aged over 80 is projected to be 426 million by 2050 according to the United Nations population prospects. As we are entering a smart-health generation, the ecosystem demands more cost-effective solutions and appropriate treatments which can be delivered at the appropriate time and location. Clinicians use technology to give more holistic solutions to an aging population and provide more accurate diagnostics. Care delivery stakeholders use data and communicate more effectively and efficiently. Patients are involved in their own treatment plans and more healthcare access is delivered to people who did not previously have access. Unfortunately, we still face issues such as the increasing cost of healthcare, aging population, limited resources and shortages of healthcare professionals in various parts of the world. In order to combat these problems, government support and spending alone is not enough. We believe that these shortages can be filled by technology, which can be our solution for ensuring sufficient healthcare for future generations. This is also the reason why we are keen on enterprises which can provide solutions to combat these issues and create positive changes in the smart-health era. Founded in Singapore, we hope to be able to leverage the geographical advantage of Asia, and put together growth opportunities for these technologies which will make them accessible globally in the long term. WE SUPPORT START-UPS POST INVESTMENTFOUNDER SUPPORT: Start-ups regularly face critical decision-making as businesses grow from continuous market feedback and unexpected situations. We understand how difficult it can be and we will work together with the founders as a team in order to assist them with scaling their company, whether from networking referrals at the R&D stage, business strategy improvement at the growth stage, or EBITDA optimisation at a later stage. We offer support to founders for the optimisation of team structure as their businesses grow so they can overcome challenges and compete globally. MANUFACTURING SUPPORT: Manufacturing is one of the most crucial aspects of any device company, but it is often where mistakes are made. We advise our companies who experience manufacturing challenges from prototyping to mass production. In order to achieve this, we provide strategic value to our portfolio companies by connecting them to cost-effective manufacturing partners throughout the plastic, PCBA, silicon/rubber and final assembly industries. Our partners are high-mix and low-volume suppliers who understand the challenges of start-ups. Outside of production, we assist companies with lower case costing, set-up and management. GOVERNANCE: Establishing a good corporate culture and necessary internal control will mitigate business losses from major risks and lay the foundations for a company to improve. In a later stage funding cycle, correct corporate governance and internal control are paramount before larger funds buy into the company’s vision and growth story. We have a complete understanding of control and our networks are comprised of global experts in financial knowledge and risk assurance who can work together with our companies. FUNDRAISING: We typically fund companies while they are still young, from their seed to their series A round. Given the heavy research and development nature of medical technology companies, they usually require additional funding in order to boost their business quickly. Post-investment, we will not only collaborate on budgets and milestone adjustments but will more importantly offer assistance with financial modeling and revenue projection. This ensures that companies gain a higher chance of future investment. Finally, we work with other larger funds all over the world who specialise in revenue growth in order to understand their needs when they select their investment targets. EXIT: We seek founders with longer-term goals and a desire to take their companies to global players. Given our evergreen nature and flexible exit strategy, we are well suited to the long operation cycle of healthcare companies. At the same time, we understand and respect that some founders have a shorter term goal of M&A to boost market shares, expand business services or leverage bigger players to scale the company. We are experienced in company buy-out considerations and offer our support to founders as long as the company fits within our investment mandate.

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

We are dedicated team of experienced investors who help to enable groundbreaking work by investing in and fostering companies and technologies that advance the future of health. Entrepreneur-friendly strategic investor that speeds access to new healthcare products and services to improve patient care Established by UNC REX Healthcare in 2012 as part of its commitment to innovation Partners with emerging companies throughout North Carolina and the U.S. Leverages the talent and subject matter experts across the UNC REX and UNC Health Care network

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery